ConductScience.org, home

Paper40802193

Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.

Yamaguchi J and 12 others. JAMA Cardiol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial. Papers, record 40802193. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40802193

Download JSON
Disease
coronary artery disorder241 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial.
PubMed
Journal
JAMA Cardiol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-14
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yamaguchi JJunichi
2Arashi HHiroyuki
3Hagiwara NNobuhisa
4Yasuda SSatoshi
5Kaikita KKoichi
6Akao MMasaharu
7Ako JJunya
8Matoba TTetsuya
9Nakamura MMasato
10Miyauchi KKatsumi
11Matsui KKunihiko
12Ogawa HHisao
13AFIRE InvestigatorsGroup

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02642419Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease StudyDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135936042
Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry.
J Arrhythm2022https://conductscience.org/library/papers/35936042PubMed
234736731Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.JACC Cardiovasc Interv2021https://conductscience.org/library/papers/34736731PubMed
324550531Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.Circ Cardiovasc Interv2014https://conductscience.org/library/papers/24550531PubMed
427959713Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.N Engl J Med2016https://conductscience.org/library/papers/27959713PubMed
531492505
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Lancet2019https://conductscience.org/library/papers/31492505PubMed
616765759
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Lancet2006https://conductscience.org/library/papers/16765759PubMed
79834303A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.N Engl J Med1998https://conductscience.org/library/papers/9834303PubMed
822813718Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation.Drug Metab Pharmacokinet2013https://conductscience.org/library/papers/22813718PubMed
939918465Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.J Am Coll Cardiol2025https://conductscience.org/library/papers/39918465PubMed
1031475793Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.N Engl J Med2019https://conductscience.org/library/papers/31475793PubMed
1121830957Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med2011https://conductscience.org/library/papers/21830957PubMed
1215842354Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost2005https://conductscience.org/library/papers/15842354PubMed
1331116032Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.Circulation2019https://conductscience.org/library/papers/31116032PubMed
1431272556Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.J Am Coll Cardiol2019https://conductscience.org/library/papers/31272556PubMed
1532865374Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.N Engl J Med2020https://conductscience.org/library/papers/32865374PubMed
1626314532Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention.J Am Coll Cardiol2015https://conductscience.org/library/papers/26314532PubMed
1732173684JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease.Circ J2020https://conductscience.org/library/papers/32173684PubMed
1831623473Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms.Expert Opin Drug Saf2019https://conductscience.org/library/papers/31623473PubMed
1912644343Oral anticoagulants in patients with coronary artery disease.J Am Coll Cardiol2003https://conductscience.org/library/papers/12644343PubMed
2038033089
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Circulation2024https://conductscience.org/library/papers/38033089PubMed

See all 32 referencesDownload CSV of references

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
RIVAROXABANCHEMBL198362Derived from the trial1https://conductscience.org/library/drugs/CHEMBL198362

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40802193

GET https://conductscience.org/api/papers/v1/40802193/references?page=2